Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.45 |
| ▸ | SMO | Q99835 | 11/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968346 | 0.89 | SMO (0.40) | CYP11B1CYP11B2SMOMEN1KMT2A | |
| SCHEMBL12841520 | 0.85 | SMO (0.44) | CYP11B1CYP11B2SMOMEN1KMT2A | |
| SCHEMBL9932498 | 0.83 | SMO (0.65) | SMOMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL9932531 | 0.83 | MEN1 (0.43) | SMOMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL9931789 | 0.82 | PTPN11 (0.43) | SMOMEN1KMT2A | |
| SCHEMBL9968459 | 0.82 | MEN1 (0.42) | SMOMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL9932468 | 0.82 | PIM1 (0.45) | SMOMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL9968319 | 0.80 | MEN1 (0.46) | SMOMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL9968445 | 0.80 | SMO (0.52) | SMOMEN1KMT2AKDM4ENPC1 | |
| SCHEMBL9933199 | 0.79 | PTPN11 (0.44) | SMOMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | CYP11B1 1338/4885CYP11B2 1556/4885SMO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.